Adamax
PEG-Semax analog · Neuropeptide (research)
What it is
A pegylated Semax analog sold by grey-market nootropic vendors as a "stronger, longer-lasting Semax". Unlike Semax itself, it has essentially no published record anywhere — it is a vendor invention built on a real molecule's reputation.
What human evidence shows
None. Not thin — none: no trials, no animal literature under this name, nothing to audit. Everything claimed for it is extrapolated from Semax plus the assumption that pegylation only changes duration. That assumption is doing all the work.
Risks
The unknowns of Semax multiplied by a modification nobody has studied, from a supply chain with no pharmacopeia standard. Intranasal self-administration of an uncharacterized peptide is the entire risk profile: nobody can tell you what it does because nobody has looked.
Legal status
US: not approved, not scheduled — pure grey-market "research chemical".
Evidence base
very early literature
Almost no published research of any kind.
- phase 3/4
- 0
- randomised
- 0
- reviews
- 0
- human trials
- 0
Counts are of published papers, not distinct trials, and measure how much research exists — not whether this works or is safe for you.
Turn Adamax into a plan that's yours
The info above is free. Membership makes it personal, the Coach answers questions about your exact stack, the Stack tracks it for you, and the Verified Sources shows you how to vet what you buy.
- ✓ AI Coach, ask anything about your stack. It does the dosing math, flags interactions, and tells you what to do next.
- ✓ Personal Stack, save your protocol, track it across devices, log doses, get a heads-up before a vial runs out.
- ✓ Verified Sources, the vetted reference for checking quality and sourcing, members only.
Cancel anytime · or save with $59.99/yr · Coach + Stack included